Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting l
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
Secondary analysis of three RTOG/NRG trials shows radiotherapy interruptions are associated with higher locoregional failure and worse overall survival in head and neck cancer, with larger absolute harms in p16‑negative and high‑stage disea
A large single-center cohort (n=7,622) shows 12.6% of head and neck cancer patients develop severe (≥RTOG grade 3) radiation-related late toxicities; modifiable factors and specialized multidisciplinary late-effects care may reduce risk and
Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue
A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living c
A multinational team developed and valued the HNC-8D, an 8-dimension, head and neck cancer–specific health utility instrument derived from EORTC QLQ-C30/H&N43. Valuation in 250 participants yielded mean absolute prediction errors of 0.0
A pooled analysis of two neoadjuvant nivolumab trials found that pathologic treatment effect >57% is associated with markedly improved 3‑year disease‑free and overall survival in HPV‑negative resectable HNSCC, suggesting pTE may be a use
Early palliative care may reduce healthcare costs in head and neck cancer patients using tracheostomy or gastrostomy tubes but does not lessen aggressive hospital care or promote home deaths at the end of life.
This review synthesizes evidence on the timing of palliative care and the use of tracheostomy/gastrostomy tubes in head and neck cancer patients, highlighting their impact on end-of-life costs, quality, and care settings.
An international cohort study developed and externally validated artificial neural networks that stratify older adults with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) treated with definitive chemoradiation. Models
A multicenter retrospective cohort shows weekly low‑dose cisplatin markedly lowers ototoxicity compared with standard high‑dose every‑3‑week cisplatin in CRT for head and neck squamous cell carcinoma, with similar two‑year survival.
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
A novel curcumin-based polymer prodrug nanoplatform enhances immunotherapy in head and neck cancer by targeting tumor cell stemness and reversing immunosuppression via synergistic photothermal, photodynamic, and ferroptosis mechanisms.
The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cel
The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurren
A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.